Payment overview · 2025
General Payments
$280.12
14 reported records · 9 companies
Healthcare provider profile · identity verified
Armando Segui, MD
Allopathic & Osteopathic Physicians|General Practice · MIAMI, FL · NPI 1730121252
Verified facts
What the public records show
CMS Open Payments records show Armando Segui, MD received $280.12 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.00 | 22.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.80 | 16.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $39.09 | 13.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.63 | 12.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.11 | 8.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.57 | 8.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.51 | 6.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.40 | 6.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.01 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $280.12 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.00 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.80 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 439 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 171 |
| Metformin Hcl | Metformin Hcl | 293 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 108 |
| Losartan Potassium | Losartan Potassium | 252 | 97 |
| Gabapentin | Gabapentin | 233 | 90 |
| Famotidine | Famotidine | 206 | 85 |
| Alendronate Sodium | Alendronate Sodium | 205 | 68 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 200 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 87 |
| Meloxicam | Meloxicam | 189 | 69 |
| Omeprazole | Omeprazole | 176 | 70 |
| Meclizine Hcl | Meclizine Hcl | 160 | 53 |
| Lisinopril | Lisinopril | 158 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 55 |
| Montelukast Sodium | Montelukast Sodium | 115 | 50 |
| Azithromycin | Azithromycin | 109 | 83 |
| Baclofen | Baclofen | 104 | 43 |
| Furosemide | Furosemide | 104 | 44 |
| Ibuprofen | Ibuprofen | 104 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 36 |
| Eliquis | Apixaban | 78 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 76 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 35 |
| Glimepiride | Glimepiride | 76 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 75 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 31 |
| Simvastatin | Simvastatin | 68 | 27 |
| Trazodone Hcl | Trazodone Hcl | 68 | 26 |
| Januvia | Sitagliptin Phosphate | 67 | 21 |
| Memantine Hcl | Memantine Hcl | 64 | 29 |
| Ammonium Lactate | Ammonium Lactate | 63 | 20 |
| Mirtazapine | Mirtazapine | 58 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 27 |
| Lactulose | Lactulose | 57 | 18 |
| Donepezil Hcl | Donepezil Hcl | 53 | 20 |
| Ozempic | Semaglutide | 52 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 52 | 17 |
| Ciclopirox | Ciclopirox | 51 | 18 |
| Mupirocin | Mupirocin | 50 | 24 |
| Folic Acid | Folic Acid | 49 | 24 |
| Tadalafil | Tadalafil | 49 | 18 |
| Celecoxib | Celecoxib | 47 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 25 |
| Glipizide | Glipizide | 46 | 21 |
| Latanoprost | Latanoprost | 46 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 18 |
| Ciclopirox | Ciclopirox Olamine | 45 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | 18 |
| Diclofenac Potassium | Diclofenac Potassium | 44 | 14 |
| Clonidine Hcl | Clonidine Hcl | 43 | 17 |
| Atenolol | Atenolol | 41 | 17 |
| Carvedilol | Carvedilol | 40 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 18 |
| Chlorthalidone | Chlorthalidone | 36 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | 16 |
| Telmisartan | Telmisartan | 36 | 12 |
| Allopurinol | Allopurinol | 35 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 17 |
| Nifedipine Er | Nifedipine | 34 | 13 |
| Nitroglycerin | Nitroglycerin | 34 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 19 |
| Acyclovir | Acyclovir | 32 | 11 |
| Methocarbamol | Methocarbamol | 31 | 15 |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Sucralfate | Sucralfate | 31 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 12 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | 11 |
| Ezetimibe | Ezetimibe | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 27 | 11 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 22 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | 12 |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | 11 |
| Sertraline Hcl | Sertraline Hcl | 24 | 17 |
| Finasteride | Finasteride | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Levofloxacin | Levofloxacin | 23 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Prolia | Denosumab | 21 | 16 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Benzonatate | Benzonatate | 16 | 14 |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.12 · 14 records | Amgen Inc. | ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, OTEZLA, REPATHA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error